VivoSeq
Oncology

High Grade Glioma

8

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

High Grade Glioma is an early-stage landscape with 8 programs across 5 companies. The most active players are GSK, Glaxo Dba Glaxosmithkline, AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Peds IMPACT: Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in Newly Diagnosed and Recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)
Not yet recruiting·UUniversity of Florida·Phase 1·NCT06946680·24 enrolled
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion
Recruiting·NNationwide Children's Hospital·Phase 1·NCT06333899·15 enrolled
Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study
Recruiting·UUniversity of Miami·Phase 1·NCT06428045·24 enrolled
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma (WHO Grade III and IV) as a Predictor of Progression
Recruiting·CCase Comprehensive Cancer Center·Phase 1·NCT05565118·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)